New systematic review identifies ART dosing characteristics associated with greatest efficacy at 48 weeks

Once-daily administration of antiretroviral therapy (ART) regimens is associated with improved efficacy when compared with regimens requiring multiple daily doses, according to a new analysis of outcomes at week 48 in almost 78,000 people living with HIV (PLHIV). Furthermore, over three-quarters of PLHIV who started once-daily ART between 2011 and 2015 were still on their first regimen and had an undetectable viral load three years later. 1